News Search Results
Jan 16, 2025, 06:56 ET HelpMeSee Expands Simulation-based Cataract Surgery Training with New Partnerships at USC and UIC
The newly launched training sites are designed to provide residents from USC and UIC—along with ophthalmology residents and surgeons from nearby programs—access to the
More news about: HelpMeSee, Inc.
Jan 16, 2025, 04:26 ET Ambulatory Surgical Centers Market to Grow by USD 25.4 Billion from 2024-2028, Driven by Cataract Surgeries - Report on How AI is Redefining the Market Landscape - Technavio
procedures and minimally invasive treatments using surgeon tools offer solutions. However, these require physician control and can be costly. Dental, ophthalmology, and other specialties use mobile operative systems for nonsurgical procedures. Diagnosis and treatment of chronic diseases are crucial, but medical
More news about: Technavio
Jan 15, 2025, 19:00 ET Innovent Receives NMPA Breakthrough Therapy Designation for IBI343 (Anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products
More news about: Innovent Biologics
Jan 15, 2025, 10:00 ET National Inventors Hall of Fame Announces Vaccine and Surfboard Innovators Among 2025 Class
tomography (OCT), a method for imaging subsurface structure of biological tissue in unprecedented detail. OCT has had a transformative impact in ophthalmology, improving the detection and management of sight-impairing eye diseases. OCT also is used in cardiology and across a growing range of applications
More news about: National Inventors Hall of Fame
Jan 15, 2025, 03:08 ET Piramal Pharma Limited Converts the Coal-Fired Steamer at its Digwal Facility to Operate on Biomass Briquettes, Advancing Decarbonization Efforts
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. For more information, visit: Piramal
More news about: Piramal Pharma Ltd
Jan 15, 2025, 03:00 ET Piramal Pharma Limited Converts the Coal-Fired Steamer at its Digwal Facility to Operate on Biomass Briquettes, Advancing Decarbonization Efforts
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. For more information, visit: Piramal
More news about: Piramal Pharma Ltd
Jan 14, 2025, 21:52 ET Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Jan 14, 2025, 12:43 ET Next Generation Gene Therapeutics (NGGT) Announces Publication of Early Clinical Trial Results for NGGT001 for the Treatment of Bietti's Crystalline Dystrophy (BCD)
JAMA Ophthalmology of the results from a dose-escalation study in patients with BCD, entitled "Safety and Vision Outcomes Following Gene Therapy for Bietti
More news about: NGGT Inc.
Jan 14, 2025, 09:00 ET all® free clear detergent Becomes the First-Ever Laundry Brand in the US to Introduce NaviLens Technology on its Packaging
https://www.all-laundry.com/NaviLens.html to read how NaviLens technology is empowering those with blindness and low vision. * American Academy of Ophthalmology About all® Sold in the United States,
More news about: all®
Jan 14, 2025, 06:00 ET Eyesafe and Lenovo to Enhance Wellbeing for Millions of Students
world-class team of eye doctors, engineers, and scientists with decades of experience in electronics, display materials, light management, optometry, and ophthalmology. The Eyesafe brand is trusted by consumers and integrated in millions of digital devices from Dell, HP, Lenovo, LG, ZAGG and more. Eyesafe is recognized
More news about: Eyesafe
Jan 13, 2025, 09:00 ET Symbio, Global Clinical Research Organization, Announces Two Key Leadership Appointments
About Symbio Symbio is a global specialist therapeutic CRO with exceptional expertise in Dermatology, Aesthetics, Wound Care, Ophthalmology, Inflammation, and Gastroenterology. The business operates across the USA and Europe,
More news about: Symbio
Jan 13, 2025, 09:00 ET ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow
positive impact the technology continues to have on the quality of life for patients," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "With the integration of the ZEISS MEL 90, surgeons can confidently care for their patients with greater workflow efficiency
More news about: Carl Zeiss Meditec AG
Jan 13, 2025, 09:00 ET ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal Refractive Workflow
positive impact the technology continues to have on the quality of life for patients," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "With the integration of the ZEISS MEL 90, surgeons can confidently care for their patients with greater workflow efficiency
More news about: Carl Zeiss Meditec AG
Jan 13, 2025, 08:31 ET AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program
macular degeneration. American Academy of Ophthalmology. 2019.6 Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72-84.7 Holz
More news about: AbbVie
Jan 13, 2025, 03:30 ET Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as Chief Scientific Officer
Matthew has over 25 years' experience in drug discovery and development across multiple target classes covering oncology, immunology, neurology, ophthalmology and metabolic disease. He joins from Storm Therapeutics — where he was Senior Vice President of Therapeutics — and has held Senior Leadership positions
More news about: Outrun Therapeutics
Jan 10, 2025, 11:03 ET University of Maryland, Baltimore and University of Maryland, College Park Announce $10 Million Joint Gift from Edward and Jennifer St. John and the Edward St. John Foundation for New Center for Translational Engineering and Medicine
James Clark School of Engineering at UMCP, and Osamah J. Saeedi, MD, clinical co-director and professor of ophthalmology and visual sciences at UMSOM. Their collaborative work using cutting-edge ophthalmologic imaging to address ocular diseases such as glaucoma exemplifies
More news about: University of Maryland
Jan 09, 2025, 07:58 ET Mabwell's Nectin-4 Targeted ADC 9MW2821 Combination Therapy Demonstrates 87.5% ORR and Granted CDE Breakthrough Therapy Designation
R&D engine, including 12 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc. Of these, 3 products have been approved and commercialized, 1 product has been filed for MA, 3 products
More news about: Mabwell
Jan 09, 2025, 07:51 ET Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Biocon Biologics' pipeline is strategically aligned to the top global therapeutic areas including oncology, immunology, diabetes, bone health, and ophthalmology, creating an opportunity for the Company to help answer unmet needs across a range of opportunities. Shreehas Tambe, CEO & Managing
More news about: Biocon Biologics Ltd.
Jan 08, 2025, 18:30 ET U.S. FDA Confirms Class 1 Resubmission of the Supplemental New Drug Application for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Jan 08, 2025, 12:00 ET Nearly 90 Physicians from MemorialCare's Long Beach Medical Center, Miller Children's & Women's Hospital Recognized by Leading Doctor's Report
otolaryngology, pediatrics, pediatric surgery, endocrinology, rheumatology, maternal/fetal medicine, enterology, gastroenterology, thoracic surgery, ophthalmology, and neonatal/perinatal medicine. "Our physicians are dedicated to delivering compassionate, family-centered care with a focus on quality
More news about: MemorialCare Long Beach Medical Center and MemorialCare Miller Children’s & Women’s Hospital Long Beach
Jan 08, 2025, 09:00 ET Beyeonics Vision Ltd. Appoints Michael Brownell as Chairman of the Board
visualization technology for Ophthalmology, announces the appointment of Michael Brownell as Chairman of the Board. This strategic appointment underlines Beyeonics Vision's commitment to advancing its technological leadership in ophthalmology and transforming surgical environments
More news about: Beyeonics Vision
Jan 08, 2025, 09:00 ET L.E.K. Consulting Announces 10 New Global Partner Promotions
area and corporate growth. Stern's expertise spans therapeutic areas with rapidly evolving standards of care, and he has extensive experience in ophthalmology, central nervous system (CNS) disorders and cardiometabolic disease. Stern holds a Ph.D. in neuroscience from the University
More news about: L.E.K. Consulting
Jan 08, 2025, 07:00 ET InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
More news about: InMode Ltd.
Jan 08, 2025, 04:55 ET China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Bladder Cancer
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Jan 08, 2025, 03:30 ET Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics
first-in-class and best-in-class therapies to the market across a wide range of therapeutic areas, including cardio-metabolic, oncology, hematology, ophthalmology, female health, dermatology, and infectious diseases. Dr. Moeller was previously Head of Global R&D and a member of the executive leadership
More news about: Antag Therapeutics